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ABSTRACT 
 With increasing age, individuals begin to experience cognitive decline, especially 
memory deficits. Given the lack of effective treatments for memory loss, a new 
promising approach includes targeting second messenger systems that play a critical role 
in cognitive processes by inhibiting phosphodiesterases (PDEs), specifically PDE11A 
since its expression is restricted to the brain. PDE11A is responsible for regulating levels 
of second messengers, such as cyclic AMP and cyclic GMP, which participate in several 
biochemical processes relating to long term memory function. Since these signaling 
cascades are controlled by PDEs that result in turning off the signaling pathway, 
inhibiting phosphodiesterases will lead to an elevated level of cyclic nucleotides and in 
turn restore memory function. Based on a PDE11A inhibitor identified during an initial 
screening, a variety of bisamide and sulfonamide analogs were synthesized to test if they 
have improved potency and selectivity for PDE11A. Given the limited information 
regarding the structure activity relationship, this data provided insight on the structure 
affects the biological activity.  

SYNTHESIS OF AMIDE AND SULFONAMIDES  
AS PDE11 INHIBITORS  
A THESIS  
Submitted in partial fulfillment of the requirements  
For the degree of Master of Science 
by
NOOR ABOUCHAKRA 
Montclair State University  
Montclair, NJ
2020 
4ACKNOWLEDGEMENTS 
First, and most of all, I would like to express my gratitude towards Dr. Rotella for his  
continued support, guidance, and expertise. 
To my committee members, Dr. Goodey and Dr. Bebbington for agreeing to read and 
evaluate my thesis.  
To my collaborator at Boston College, Dr. Charles Hoffman, for carrying out the 
biological testing.  
To my lab partners; thank you for the good atmosphere and spirit.  
Lastly, I wish to thank my family and friends for their unconditional support.
5TABLE OF CONTENTS 
               Page 
I. Acknowledgements………………………….………….…….……..…….……….…4 
II. Table of Contents………………………….…….……….…….….………..….…..…5 
III. List of Figures……………….………….………….……………….…….…….…….6 
IV. Introduction.…………….…………….………………….…………..………….……7 
V. Research Plan……….…………………….……………….…..…….….……..…….14 
VI.  Synthesis of Amide and Sulfonamide Derivatives.…………..….……..…….…..…18 
VII. Results……………………….…………….……..….………….………….….……23 
VIII.Conclusion and Further Studies…..…………………..….…….….….….…..….….27 
IX. References….….………………….…..…….………….…..….……..…………..….29 
X.  Experimental Procedure..………………..………….……….….……..……………32 
XI.  NMR spectra………………….………….….……….…………….….……….……47 
XII. Mass spectra.…..…………….…..………….…..…………………….….….….…..58
6LIST OF FIGURES 
           Page 
1   PDE11A4 mRNA expression in rodent cells.…………………….……………………9 
2   Hippocampal PDE11A expression……………………..……………………………..10 
3   PDE11A Inhibitors……………………….………….…………………….………….11 
4   5FOA and in vitro assays of 1 and derivatives……………………………………….13 
5   5FOA and in vitro assays of 3 and derivatives.………….……………….…………..13 
6   Anthranilamide, potent PDE11 inhibitor………………………….……….…………14 
7   Examples of primary and secondary amines………..……………….…….…………15 
8   Bisamide PDE11 inhibitor synthesis….……………………….……….…….………15 
9   Synthesis of N-sulfonamido amide derivatives.…………………..………………….16  
10   Synthesis of sulfonamido amide derivatives………………………..……..………..16 
11   First synthetic route explored for bisamide analogs.……………………..…………18 
12   Primary and secondary amines implemented in bisamide analogs…………..……..18 
13   Primary bicyclic amines implemented in bisamide and sulfonamide analogs…..….19 
14   Third synthetic route investigated for bisamide derivatives…………..………….…20 
15   Synthetic route applied for sulfonamido derivatives..…………………………..…..20 
16   First synthetic route explored for N-sulfonamido analogs.………..………………..21 
17   Second synthetic route explored for N-sulfonamido analogs….……………………22 
18   Analogs sent for biological testing………………………….……………………….23 
19   PDE11A response curves………..………………………….……………………….24 
20   PDE10A response curves………………..……….…….…..……………….…….…25
7Introduction 
 For decades, statistics have shown that with increasing age comes the possibility 
of developing cognitive impairment, specifically effects on memory or language. The 
mechanism of cognitive impairment is not yet fully understood seeing as each case varies 
in symptom severity (1). Studies have shown associative long-term memories (aLTMs) 
are more susceptible than recognition memories for individual items (rLTMs) (2). 
Associative long-term memories are associated with verbal along with non-verbal stimuli 
such as faces and names. Many people experience memory deficits as there is no drug 
capable of counteracting or reversing the effect so exploring an alternative hypothesis is 
essential. This new approach involves inhibiting phosphodiesterase 11A (PDE11A) thus 
increasing the intracellular levels of second messengers such as cyclic AMP (cAMP)  and 
cyclic GMP (cGMP) responsible for signaling pathways involved in long term memory 
function. Given that PDE11A is largely expressed in the ventral hippocampus in mice and 
human brain, it provides a starting point for the discovery of an inhibitor that prevents or 
reverses age related cognitive decline of aLTMs (3, 4). Inhibition of the enzyme will lead 
to elevated levels of intracellular cyclic nucleotides, thereby restoring and/or enhancing 
cellular function in this brain region.  
 Phosphodiesterase enzymes (PDEs) catalyze a hydrolysis reaction converting a 
cyclic nucleotide into a nucleoside monophosphate. These enzymes function by 
activating a molecule of water to hydrolyze the 3’,5’-cyclic phosphodiester bond in the 
cyclic nucleotide to yield a nucleoside monophosphate. More specifically, once 
nucleophilic activation of water occurs, a SN2 displacement follows at the phosphorus 
8atom cleaving the phosphate ester bond. Each phosphodiesterase enzyme consists of a C-
terminal catalytic domain, an N-terminal regulatory domain, and a COOH terminus. The 
catalytic domain consists of a highly conserved amino acid sequence, HD(X2)H(X4)N, 
which also includes cations Zn2+ and Mg2+ binding domains. On the other hand, the N-
terminal amino acid sequence varies significantly amongst different isoforms. The 
variation within the regulatory domain is speculated to be responsible for the difference 
in function of each isoform of the enzyme. For example, PDE1 consists of a calmodulin 
binding domain while GAF regulatory domains that are involved in cGMP binding are 
found in PDE11 (5). 
 Intracellular second messengers such as cyclic AMP (cAMP) and cyclic GMP 
(cGMP) are required to transmit information from neurotransmitters that bind to cell 
surface receptors (6). PDEs regulate these second messengers which, in turn, regulate 
various functions within and between cells (5). For example, cyclic nucleotides regulate 
proliferation and differentiation, as well as cognitive functions. Phosphodiesterases are 
responsible for regulating phosphorylation by protein kinases as well as controlling the 
rate of cyclic nucleotide hydrolysis, thus controlling substrate availability. Additionally, 
second messengers are highly significant signaling molecules that are released by cells in 
response to specific stimuli such as the release of nitric oxide or the activation of G-
protein coupled receptors. Inhibition of the enzyme would directly result in a rise in the 
levels of cyclic nucleotides leading to an improved response to stimuli and signaling. 
This is expected since the product of the enzymatic reaction is inactive as a second 
messenger resulting in termination of the signaling pathways. 
9 There are eleven known types of mammalian phosphodiesterase enzymes (PDE1 - 
PDE11) (5). Each subfamily may consist of multiple isoforms that are identified using a 
capital letter. The enzymes specific to cAMP include PDE4, PDE7, and PDE8 while 
cGMP specific enzymes include PDE5, PDE6, and PDE9. The remainder of the enzymes 
process both cAMP and cGMP, with certain preferences for one messenger over the other. 
PDE11 consists of a single gene that is spliced into four variants, PDE11A1 to PDE11A4, 
all of which process both types of second messengers. The amino terminal domain is 
responsible for catalytic function, and contains two GAF domains alongside two 
phosphorylation sites. The GAF-A domain is responsible for binding to cGMP while 
GAF-B domain is required for homodimerization. Two serine residues (S117 and S162.) 
found only in the PDE11A4 isoform are phosphorylated by cAMP dependent protein 
kinase (PKA) and cGMP dependent protein kinase (PKG), which are speculated to play a 
significant role of regulation of this enzyme. Evidence shows that if both sites are 
phosphorylated, the GAF domain has an increase in affinity for cGMP, possibly due to a 
conformational change occurring (7). 
 The PDE11 subfamily is mainly expressed in skeletal muscle, prostate, and brain 
cells but the focus at hand is on PDE11A4, the longest isoform, which is solely expressed 
within human brain cells. This isoform is found to be 
approximately 95% homologous across mouse, rat, and 
human cells (9). According to a study done on rodents 
by the Kelly lab, the is found in the VHIPP (ventral 
hippocampal formation) with 3-10 fold enrichment 
Figure 1. PDE11A4 mRNA 
expression in rodent cells (7, 8).
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when compared to expression in DHIPP (dorsal hippocampal formation), making this a 
unique drug target since the hippocampal is an essential structure in associate long term 
memories (Figure 1) (7). Rodent mRNA expression studies show PDE11A4 is found in 
ventral hippocampal formation within neurons of CA1, subiculum, and the adjacently 
connected amygdalohippocampal area with only the nervous system showing a signal for 
PDE11A4. Studies have demonstrated how cAMP and cGMP singling is reduced in older 
and demented hippocampus’ of rodents as well as humans as seen in Figure 2 (10, 11). 
Taking everything into account, it is possible to target PDE11A4 without affecting 
signaling in other regions of the brain therefore solely reestablishing cyclic nucleotide 
signaling.  
 Currently, there are only a select few inhibitors that specifically target PDE11A, 
quantifying the significance of the research project at hand (Figure 3). A screening was 
completed on approximately 200,000 compounds for PDE11 inhibitors where three 
compounds were identified as PDE11 inhibitors based on their structure activity 
relationship: anthranilamide 1, pyridopyrazole 2, and pyrimidinyl pyrrole 3 (12). 
Additionally, separate studies have been done on tadalafil 4, sildenafil 5, and vardenafil 6 
Figure 2. Hippocampal PDE11A expression is increased in A) Old 
vs. young mice, B) adult (18-40yrs) vs. prenatal humans, and C) 
demented vs. non-demented aged humans (>75yrs) (10, 11). 
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which are PDE5 inhibitors 
that also have the capability 
of inhibiting the PDE11A 
where tadalafil was shown to 
be the most potent inhibitor 
with an IC50 of 73 nM (12). 
In addition, dipyridamole 7
and E4021 8 are a l so 
relatively potent PDE11 
inhibitors with cAMP and cGMP as substrates with an IC50 of 0.8 μM and 1.8 μM when 
studied with PDE11A3 and PDE11A4 (13). As for the project at hand, in order to analyze 
the biological activity of the synthesized compounds as inhibitors, a 5-fluoro-orotic acid 
growth assay was utilized. The 5FOA growth assay was proven to provide accurate 
results for PDE4, PDE7, PDE8, and PDE11A inhibitors (14 - 16). This yeast-based assay 
is advantageous for mammalian cells since it analyzes the growth behavior of the yeast 
strains which in turn correlates to the activity of PDEs. Compounds that respond well in 
this assay as PDE inhibitors are cell permeable, an important feature essential for 
PDE11A inhibitors, do not interact with other yeast proteins, and are chemically stable 
since the growth period is measured up to 48 hours after incubation.   
 The three compounds identified in this screen as PDE11A inhibitors, are 
anthranilamide 1, pyridopyrazole 2, and pyrimidinyl pyrrole 3. The bisamide compound 1
was determined to be a more potent PDE11A inhibitor with an IC50 of 10 nM as well as a 
12
PDE10A inhibitor, whereas pyridopyrazole 2 and pyrimidinyl pyrrole 3 are more 
selective PDE11 inhibitors with an IC50 of 180 nM and 110 nM. It is worth noting the 
difference in selectivity of the above PDE11A inhibitors, compared to inhibition of 
PDE10A. For instance, 1 is considered a dual PDE11/PDE10 inhibitor since it exhibits an 
IC50 of 2 µM for PDE10A and 2 displays an IC50 of 35 µM for PDE10A. (14, 17). Hence, 
PDE11A inhibitors synthesized must also be tested for PDE10 inhibition. All three 
compounds have acceptable molecular weights, total polar surface area (TPSA) values 
less than 90, and the potential for central nervous system permeability based on an 
MDCK-1 assay. Anthranilamide 1 and pyridopyrazole 2 also show low to moderate water 
solubility with inadequate metabolic stability. On the other hand, pyrimidinyl pyrrole 3 
has poor water solubility but sufficient metabolic stability. As for the cLogP values, 
compound 1 presented an ideal value of 3.64 however compound 2 and 3 had values of 
5.33 and 6.78. These features are important in order to establish the compounds ability to 
permeate the blood brain barrier where very tight cellular spacing limits paracellular 
permeability, both molecular weight and TPSA should be minimized to the extent 
possible. The partition coefficient between n-octanol and water, cLogP, is utilized to 
gather information about the compound’s hydrophilicity to give further insight on cell 
absorption and permeation. 
 Given the above characteristics and structure of each compound, each one allows 
for optimization at multiple sites. Compound 1 was investigated alongside analogs with 
various substituents in position R as seen in Figure 6. PDE11A inhibition activity 
observed for both analogs (1a) and (1b) had IC50 values of 50 nM and 10 nM. In contrast, 
13
when testing compound 3 analogs, PDE11A inhibition activity displayed for (3a) and 
(3b) had IC50 values less than 0.2 μM. The data from the 5FOA assays presented 
evidence for structure activity between the substrate and enzyme leading to the 
conclusion that analogs based on the structures at hand will provide key starting points 
for synthesis of a biologically active molecule capable of PDE11A inhibition. 
Figure 4.  5FOA and in vitro assays of 1 and derivatives. 
 
Figure 5.  5FOA and in vitro assays of 3 and derivatives. 
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Research Plan 
The key aim of this research project is to provide the foundation of a PDE11A 
inhibitor that is both potent along with highly selective. Due to the fact that molecules 
active against PDE11A for cognitive effects will have to efficiently penetrate the blood 
brain barrier, molecular characteristics play an important role in compound design. These 
characteristics include molecular weight [generally < 400 g/mol], total polar surface area 
(TPSA) [≤ 90 Å], cLogP [≤ 3.5], and efflux ratio (reflecting the ability of the compound 
to be actively pumped out of the CNS) [MDCK ratio ~1:1]. These features will give 
insight on a compounds potential for cell absorption and permeation.  
 This research 
w i l l f o c u s o n 
anthranilamide 1 since 
it is the most potent 
PDE11A inhibi tor 
identified in the screen and because there is little available structure activity information. 
The anthranilamide 1 also has favorable characteristics including a molecular weight of 
370 g/mol, cLogP of 3.64, and a TPSA of 74 with potential for brain permeability. Since 
1 is considered a dual PDE11/PDE10 inhibitor, the modifications will need to be assessed 
for improvement of PDE11 selectivity as well as metabolic stability. Optimization of 
bisamide will occur with manipulations in positions R1 and R2 as seen in Figure 6. In 
position R1 various primary and secondary amines will be applied that consist of 
heterocyclic compounds such as piperidine and pyrazine (Figure 7). Implementing these 
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specific types of amines will aid in 
understanding whether structures 
similar to the methylbenzimidazole 
in the original compound affects 
activity of the enzyme. It is 
anticipated that tertiary amide 
analogs would be less susceptible to hydrolysis while on the other hand the removal of an 
H-bond donor may enhance brain penetration. However, as for position R2 a variety of 
benzene derivatives such as substituted phenyl heterocycles will be applied.  
 Synthesis of anthranilamide analogs can be carried out beginning with isatoic 
anhydride 9 reacting with an amine followed by amide formation using an acid chloride. 
Another straightforward route for amide formation that can be explored begins with an 
ortho-nitro acid chloride 11 reacted with an amine. This will be followed by a nitro 
reduction and acylation as shown in Figure 8. The modifications will permit us to 
compare how primary, secondary, and sterically hindered amines improve selectivity and 
also metabolic stability. 
 As an alternative to bisamide analogs, we plan to explore sulfonamide derivatives 
because of their improved stability to hydrolysis and hydrogen bonding potential. In this 
16
case, the reaction mechanism will be fairly similar to those previously explained. Once 
again, reactions will be carried out starting with isatoic anhydride 9 with the addition of 
an amine, followed by sulfonamide formation using a sulfonyl chloride rather than an 
acid chloride (Figure 9). As 
drawn out in Figure 10, the 
s e c o n d a m i d e c a r b o n y l 
position will be substituted 
with a sulfonamide by reacting 
a 2-ni t robenzenesulfonyl 
chloride 13 with an amine of 
choice initially. Once the 
desired product is synthesized, 
a nitro reduction followed by 
an acylation should derive the desired sulfonamide derivative. This will permit a direct 
comparison of SAR between a single functional group change, amide versus N-
sulfonamide derivatives. This specific relationship analysis can only be achieved by using 
the primary amine from the anthranilamide 1, 2-amino-1-methylbenzimidazole in 
synthesizing both compounds, 12 and 14. Following this, amines listed in Figure 7 will 
then be implemented to assess the second key region for SAR.  
 All compounds will be tested for PDE11A inhibition using the previously 
described fission yeast-based 5FOA growth assay used to identify lead PDE11A 
inhibitors. Initially, the compounds will be tested in a dose response at final 
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concentrations 0.5 to 62.5 µM, however the range may change depending on the 
development of potent analogs. Simultaneously, each compound will be tested against 
counter-screening strains that express either PDE5A or PDE10A based on prior studies 
revealing cross-reactivity from PDE11A lead inhibitors. Based upon the data in Figure 6, 
the standard OD600 range for DMSO treated cells is ~0.2 opposed to ~1.2 for PDE 
inhibited cells. An ED50 will be assigned based on the concentration of the compound 
required to generate an OD600 of 0.7. If compounds display an ED50  <2µM for PDE11A 
and >62.5µM for PDE5A and PDE10A, each will undergo further analysis by 5FOA 
assays using yeast strains that express PDE1C, PDE2A, PDE3B, PDE4D, PDE7A, 
PDE8A, and PDE9A. Moreover, if a compound shows no activity against PDEs (e.g. the 
ED50 values >62.5µM) except for PDE11A then it will be evaluated via in vitro enzyme 
assays to measure IC50 values. Those compounds with IC50 values against PDE11A <50 
nM will advance to ADME property evaluation.
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Synthesis of Amide and Sulfonamide Analogs  
Synthesis of anthranilamide 1 analogs first started with modifications in position 
R1 to analyze the SAR using a variety of amines. A two-step scheme was carried out 
beginning with the conversion of a carboxylic acid to an acid chloride (Figure 11). The 
reaction of 2-benzamidobenzoic acid 15 with oxalyl chloride in methylene chloride 
substituted the hydroxyl group with a chloride ion to form an acid chloride. In the 
following step, the desired 
product, 2-benzamidobenzoyl 
chloride 16 was directly treated 
with 4-phenylpiperidine and 
triethylamine in DMF resulting in 
N-(2-(4-phenylpiperidine-1-
carbonyl)phenyl)benzamide 17. 
Based on the success of this 
reaction, similar steps were repeated for various primary and secondary amines (Figure 
12). The only difference in synthesizing the remainder of the bisamide analogs (18-23) 
using amines in Figure 12, was the use of acetonitrile rather than N,N-
dimethylformamide (DMF) for ease of workup. Every compound was analyzed by 1H 
NMR to confirm that the desired product was synthesized. Based on this analysis, 
reaction products were submitted for biological testing by our collaborator at Boston 
College.   
19
 A s m e n t i o n e d a b o v e , 
identifying bicyclic heterocyclic 
amines that could substitute for 2-
amino-1-methylbenzimidazole was 
one of the goals to be achieved during 
the project. In Figure 13, the four primary amines shown were explored in synthesis of 
both bisamide and sulfonamide analogs. These amines were investigated for preparation 
of bisamide derivatives. In the same manner as above, all four acylation reactions were 
attempted in identical conditions. Despite the fact that all previous reactions were 
successful, in this case, only acylation with 2-aminobenzothiazole (24) was effective. 
Based on TLC analysis, no product formation occurred when reacting the acid chloride 
with 1-methylindazol-3-amine, 2-aminobenzoxazole, or 1,2-benzisoxazol-3-amine. The 
lower reactivity of these amines might stem from their low nucleophilicity. For instance, 
2-aminobenzoxazole and 1,2-benzisoxazol-3-amine have increased electronegativity 
making these amines less nucleophilic whereas 2-aminobenzothiazole is less 
electronegative making it more nucleophilic which coincides with the results of the 
reactions.  
 While detailed study of reaction conditions suitable for these heterocyclic amines 
was not carried out, alternative routes with other starting material were briefly evaluated 
using isatoic and phthalic anhydride. Isatoic anhydride has been widely used for 
preparation of heterocyclic amides, but unfortunately, none of the amines reacted in 
toluene or dioxane at elevated temperature.  
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 In a final attempt to 
prepare bisamide analogs, a 
three-step scheme (Figure 14) 
was investigated beginning 
w i t h 2 - a m i n o i n d a n 
h y d r o c h l o r i d e a n d 2 -
nitrobenzoyl chloride 11 in pyridine to give N-(2,3-dihydro-1H-inden-2-yl)-2-
nitrobenzamide 25 as the acylation product in the first step. Considering pyridine is a 
moderate nucleophile for carbonyl groups, it was used as a catalyst in the acylation step. 
More specifically, the nitrogen atom in pyridine is nucleophilic since the lone pair of 
electrons on nitrogen are not delocalized around the ring. In the following step, catalytic 
hydrogenation reduced the aromatic nitro group to an aniline. In the final step of this 
synthetic route, nucleophilic addition/elimination of 2-amino-N-(2,3-dihydro-1H-
inden-2-yl)benzamide with benzoyl chloride 26 resulting in the final bisamide analog, 2-
benzamido-N-(2,3-dihydro-1H-inden-2-yl)benzamide 27, was successfully produced and 
prepared for further testing. 
 Simultaneously while 
identifying synthetic routes 
that work effectively for 
generating bisamide analogs, 
synthetic routes useful for 
sulfonamido derivatives were 
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also explored using similar starting material as shown in Figure 15. The first step 
involved sulfonamide formation using 2-nitrobenzenesulfonyl chloride 13 and 2-
amino-1-methylbenzimidazole in chloroform with triethylamine and DMAP added as a 
catalyst, successfully producing 28. This was followed by catalytic reduction of the 
aromatic nitro group to an aniline in acetic acid. Solubility of this compound was initially 
troublesome as it would not fully dissolve in methanol or ethanol leading to the use of a 
more polar solvent such as acetic acid with the final hydrogenation product being an 
acetate salt 29. Once again, the last step encompasses amide formation from nucleophilic 
addition/elimination with benzoyl chloride to give the sulfonamide derivative 30. A 
similar approach with slightly different reaction conditions was applied using 2-
aminoindan to produce the final product, N-(2-(N-(2,3-dihydro-1H-inden-2-
yl)sulfamoyl)phenyl)benzamide 33. Both final products from this synthetic approach 
were characterized by 1H NMR and submitted for biological testing to compare SAR at 
the two optimization sites.  
 The final goal was to synthesize derivatives with an N-aryl-sulfonamide in the 
second amide carbonyl position based on the original anthranilamide structure. Initially, a 
three step synthetic route 
illustrated in Figure 16 
starting sulfonylation of the 
amine in anthranilic acid 34 
b y r e a c t i n g w i t h 
benzenesulfonyl chloride 35 
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to gave ortho-sulfonylaminobenzoic acid 36. Following the same procedures from prior 
experiments, the product was then converted to an acid chloride using oxalyl chloride 
followed by a final acylation step with 2-amino-1-methylbenzimidazole in acetonitrile. 
TLC analysis of the reaction revealed no product, with starting material remaining 
essentially unchanged. In view of the fact that the first trial of experiments were not 
successful, an alternative route was then taken as displayed in Figure 17. Similar to the 
procedure in Figure 14, the same type of reaction was carried out. The solubility of 39 
was very limited in solvents 
compa t ib l e w i th ca t a ly t i c 
hydrogenation. After multiple 
attempts, the compound dissolved 
in a 9:1 mixture of ethyl acetate 
and methanol with heating and 
the compound remained in solution after cooling. This allowed the nitro group to be 
efficiently reduced, followed by acylation of intermediate 40 with benzenesulfonyl 
chloride. In view of the effectiveness of the scheme outlined, it was repeated once more 
with 2-aminoindan as the choice of amine to give the final sulfonamide derivative 42. All 
intermediate and final compounds described were analyzed by 1H NMR to confirm 
presence of the appropriate product before being sent for biological testing. 
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Results and Discussion  
Over the course of the project, a total of thirteen analogs were sent for biological 
testing to analyze whether each compound showed activity for PDE11A inhibition. From 
the thirteen compounds synthesized, nine of them are bisamide analogs while the 
remaining four are sulfonamide derivatives as illustrated in Figure 18 which were 
generated using ChemDraw. The molecular weight of the majority of the compounds fall 
close 400 g/mol with a maximum of 406 g/mol, not far off from the desired value. TPSA 
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takes into account the sum of surfaces of polar atoms within the compound where a lower 
value corresponds to a better ability to penetrate the blood brain barrier. The TPSA for the 
analogs synthesized ranges from 49 to 90 indicating the molecules have the capability of 
permeating the cell membranes of cells and act on the receptors in the central nervous 
system. Equally important, the cLogP   characterizes a compounds hydrophilicity where a 
lower value such as 3.5 is ideal. Amongst the compounds sent for testing, 18 shows 
highest hydrophilicity with a value of 0.643 indicating notable absorption or permeation.  
 5FOA assays were utilized to test the compounds inhibition against 
phosphodiesterase enzymes. All the 
compounds were tested in a dose 
response at final concentrations 0.5 
to 62.5 µM with DMSO as the 
negative control since it will not 
produce any results. All analogs 
w e r e c o m p a r e d t o 1 , t h e 
anthranilamide PDEllA inhibitor 
discovered during the initial 
screening, which was used as a 
positive control. The first graph 
shown in Figure 19 displays the 
data for the activity of bisamide 
analogs (17 through 24) for 
25
PDE11A inhibition. Majority of the compounds displayed no activity, resembling the 
negative control except for compounds 17, 19, and 20 which presented weak inhibition 
for PDE11A compared to 1. The next PDE11A response curve presents data generated for 
the bisamide and sulfonamide analogs consisting of 2-aminoindan (27, 33, and 42). 
Given that the compounds exhibit no activity for inhibition even at higher concentrations 
and activities are almost identical to the negative control, suggests that these three 
compounds are inactive as PDE11A inhibitors. The final response curve of Figure 19 
d i s p l a y s d a t a o b s e r v e d f o r 
sulfonamide derivatives with 2-
amino-1-methylbenzimidazole, 30 
and 41. The same trend was observed 
as the previous plot where the 
compounds displayed no inhibition 
activity for PDE11A.  
 In addition to assessing 
c o m p o u n d s a g a i n s t P D E 11 A 
inhibition, each compound was also 
tested for PDE10A inhibition, to 
further provide information on the 
selectivity of the analogs at hand 
(Figure 20). Bisamide analogs 17 to 
24 displayed no activity with the 
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exception of 24 that showed weak inhibition. Comparatively, 24 did not exhibit 
maximum activity for PDE11A inhibition indicating this analog is not as potent or 
selective for PDE11A as desired yet further modification to optimizations site R1 may 
improve these factors. As for the sulfonamide derivatives presented in the following two 
graphs, only 30 and 41 show minor inhibition activity for PDE10A compared to the 
positive control at increasing concentrations. As a whole, it is clear the bisamide analogs 
with heterocyclic amines in position R1 were very weak to inactive for PDE11A and 
PDE10A inhibition, therefore the analogs are neither selective or potent as desired. 
Likewise, both sulfonamide derivatives with 2-aminoindan appeared to follow the same 
trend as the bisamide analogs. With regards to the sulfonamide derivatives with 
methylbenzimidazole, both showed no inhibition for PDE11A but displayed weak 
inhibition for PDE10A indicating these derivatives did not improve selectivity. 
27
Conclusion and Further Studies 
 Overall, the aim of the project is to provide the foundation for discovery of a 
novel PDE11A inhibitor with drug like characteristics. Phosphodiesterases play a role in 
converting cyclic nucleotides into a nucleoside monophosphates, consequently 
inactivating the signaling pathways of two key second messengers, cAMP and cGMP. 
With all things considered, if able to inhibit PDE11A, it would then be possible to 
increase the levels of second messengers in brain cells. It is important to note that 
PDE11A is a potential drug target because it has the capacity to restore normal cyclic 
nucleotide signaling in the brain caused by age related cognitive impairment without 
affecting any other signaling in the brain. This is due to the fact that this isoform is 
exclusively expressed in the ventral hippocampal formation of mice cells. Being that 
there is no drug on the market capable of treating or preventing the mechanism that 
causes memory loss, the discovery of a novel PDE11A inhibitor could possibly reverse or 
prevent the effects of memory loss which affects millions of people worldwide. Certain 
criteria should be met by the inhibitor such as good blood brain barrier penetration, water 
solubility, metabolic stability, and hydrophilicity which can be assessed by TPSA, cLogP, 
and efflux ratio [MDCK ratio 1:1].  
 By understanding the structure activity relationship between lead candidates from 
preliminary data, specifically the anthranilamide 1 and phosphodiesterase, synthesis of 
analogs was performed in hopes of obtaining greater potency and selectivity for PDE11A. 
Modifications carried out solely in position R1 of the anthranilamide proved to be largely 
to be very weak to inactive for PDE11A inhibition. Based on the results from the 5FOA 
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assays, the starting bisamide does not appear to be a practical lead for discovery of 
PDE11A inhibitors since no active analogs were identified. On the other hand, 
sulfonamide derivatives with methylbenzimidazole are still a key interest even though 
both analogs displayed weak to no inhibition in assays for both PDE11A and PDE10A. 
More detailed research needs to take place prior to determining whether this approach is 
useful in identifying a PDE11A inhibitor.  
 Provided that none of the bisamide or sulfonamide analogs proved to be active 
PDE11A inhibitors, further research can be carried out by widening the characterization 
of lead candidates. One option involves synthesizing further analogs based on the 
anthranilamide 1 such as modifying position R1 with varying amines or R2 with 
substituted phenyl heterocycles and/or replacing amide positions with sulfonamides. 
Since an experimental procedure with suitable reaction conditions for synthesizing 
sulfonamides in both positions has been determined, this permits rapid synthesis of these 
analogs. Modifying these optimization sites individually or simultaneously will provide 
further information on the structure activity relationship in the three key regions. 
Additionally, an alternative approach may be taken where the focus of the project can be 
switched to preparing analogs based on pyrimidinyl pyrrole 3 which showed to be a 
selective PDE11 inhibitor during the initial screening. Given the limited information of 
SAR, further modifications involving replacement of the phenyl with substituted phenyls 
or short alkyls or replacing the amine with primary or secondary heterocycles can be 
pursued. Taking everything into consideration, further optimizations of either 1 or 3 
should give insight into developing a novel PDE11A inhibitor. 
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Experimental Section  
 The solvents and reagents were purchased from commercial suppliers (Acros 
Organics, Alfa Aesar, Combi-Blocks, Fisher Chemical, Sigma-Aldrich, TCI) and used 
without further purification. The reactions were all monitored by thin layer 
chromatography run on Silica XG TLC plates, aluminum backed, coated with silica gel 
(200 um) and visualized under UV light (254 nm) with chemicals and stains. Crude 
mixtures were purified either by recrystallization or by flash column chromatography 
using CombiFlash RF+ with RediSep Rf columns ranging from 4 grams to 40 grams. 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker Spectrospin 400 
MHz for 1H at room temperature with solvent peaks as reference. Chemical shifts are 
reported in parts per million (ppm). The splitting patterns in 1H NMR data are reported in 
the following order: multiplicity (s, singlet; d, doublet; dd, double doublet; t, triplet; m, 
multiplet) and number of protons. LC-MS was performed on two instruments: an Advoin 
expression CMS with Acquity UPLC H-class system and a Shimadzu where the samples 
were run in methanol.  
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General Procedures 
i. 2-benzamidobenzoyl chloride 16: 
In a 50 mL round bottom flask, 2-benzamidobenzoic acid (200.5 mg, 0.829 mmol, 1.0 
mol equiv) and a catalytic amount of DMF (one drop) were suspended in methylene 
chloride (5 mL). To the solution, oxalyl chloride (137.2 mg, 1.080 mmol, 200.5 μL, 1.3 
mol equiv) was carefully added through a micropipette. The mixture was rapidly stirred 
at room temperature under nitrogen for approximately three hours. In order to remove the 
residual methylene chloride, the sample was concentrated producing a white powder and 
placed on a high vacuum pump for an hour. The desired product was obtained in 92% 
yield (200 mg, 0.077 mmol) and used without further purification.  
ii. N-(2-(4-phenylpiperidine-1-carbonyl)phenyl)benzamide 17: 
In a reaction vial, 2-benzamidobenzoyl chloride (100 mg, 0.386 mmol, 1.2 mol equiv) 
was added to a solution of 4-phenyl piperidine (78.3 mg, 0.463 mmol, 1.0 mol equiv) and 
triethylamine (54.5 mg, 0.540 mmol, 40 μL, 1.4 mol equiv) in DMF (5 mL). The vial was 
stirred in an oil bath heated to 80°C overnight. The following day, once the reaction was 
cooled to room temperature, ethyl acetate (20 mL) was added to the resulting reaction 
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mixture. The organic layer was washed with water (30 mL), then brine (10 mL) and dried 
over sodium sulfate. The filtered and concentrated light brown solid was purified by flash 
column chromatography on silica eluting with Hexane/EtOAc (6:1). The reaction yielded 
50 mg (0.133 mmol, 34%).
1H NMR (CDCl3): δ 1.71 (s, 3H, 1), δ 1.72 (s, 2H, 2), δ 2.79 (d, 2H, 3), δ 4.09 (s, 1H, 4), 
δ 4.88 (s, 1H, 5), δ 7.15 - 7.26 (m, 7H, 6), δ 7.52 (m, 4H, 7), δ 7.90 (d, 2H, 8), δ 8.47 (d, 
1H, 9), δ 10.05 (s, 1H, 10) 
iii. 2-benzamido-N-(pyrazin-2-ylmethyl)benzamide 18: 
Experimental procedure for 17 was repeated here.  
2-aminomethyl pyrazine (54.4 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl 
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol, 
40 μL, 1.4 mol equiv) in DMF (5 mL) gave 18 as a white solid. Purification by flash 
column chromatography (95:5 DCM, Methanol) yielded 40 mg (0.120 mmol, 31%).
1H NMR (CDCl3): δ 4.84 (s, 2H, 1), δ 7.09 (m, 1H, 2), δ 7.49 (m, 3H, 3), δ 7.68 (d, 1H, 
4), δ 7.70 (s, 1H, 5), δ 8.00 (d, 2H, 6), δ 8.56 (s, 2H, 7), δ 8.72 (s, 1H, 8), δ 8.82 (d, 1H, 
9), δ 12.14 (s, 1H, 10) 
iv. N-(2-(3-benzylpyrrolidine-1-carbonyl)phenyl)benzamide 19: 
To a reaction vial, 2-benzamidobenzoyl chloride (100 mg, 0.386 mmol, 1.2 mol equiv) 
was added to a solution of 3-benzyl pyrrolidine (78.9 mg, 0.463 mmol, 1.0 mol equiv) 
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and triethylamine (54.5 mg, 0.540 mmol, 40 μL, 1.4 mol equiv) in acetonitrile (5 mL). 
The reaction was placed in an oil bath heated to 80°C and stirred overnight. The 
following day, ethyl acetate (25 mL) was added to the resulting reaction mixture. The 
organic layer was washed with 1 N HCl (20 mL), then brine (20 mL) and dried over 
sodium sulfate. The filtered and concentrated white solid precipitate was purified by flash 
column chromatography on silica eluting with Hexane/EtOAc (3:1). The reaction yielded 
91 mg (0.237 mmol, 62%).
1H NMR (CDCl3): δ 1.65 (m, 1H, 1), δ 2.00 (d, 1H, 2), δ 2.42 (t, 1H, 3), δ 2.62 (m, 1H, 
4), δ 2.72 (t, 1H, 5), δ 3.38 (m, 1H, 6), δ 3.60 (m, 2H, 7), δ 3.76 (m, 1H, 8), δ 7.08 - 7.28 
(m, 6H, 9), δ 7.51 (m, 5H, 10), δ 7.99 (d, 2H, 11), δ 8.55 (d, 1H, 12), δ 10.83 (s, 1H, 13) 
v. (S)-N-(2-(3-phenylpiperidine-1-carbonyl)phenyl)benzamide 20: 
Experimental procedure for 19 was repeated here.  
(S)-3-phenylpiperidine (91.5 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl 
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol, 
40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 44 mg (0.115 mmol, 30%) of 20 as a 
white powder. 
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1H NMR (CDCl3): δ 1.76 (m, 4H, 1), δ 2.08 (m, 1H, 2), δ 2.82 - 3.07 (d, 4H, 3), δ 4.03 
(s, 1H, 4), δ  4.81 (s, 1H, 5), δ  7.20 (s, 2H, 6), δ 7.26 (m, 2H, 7), δ 7.51 (m, 5H, 8), δ
7.95 (t, 2H, 9), δ 8.47 (d, 1H, 10), δ 10.09 (s, 1H, 11) 
vi. (R)-2-benzamido-N-(1-phenylethyl)benzamide 21: 
Experimental procedure for 19 was repeated here.  
D-(+)-alpha-methylbenzylamine (59 mg, 0.463 mmol, 1.2 mol equiv) and 2-
benzamidobenzoyl chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine 
(54.5 mg, 0.540 mmol, 40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 57 mg (0.166 
mmol, 43%) of 21 as a white precipitate. 
1H NMR (CDCl3): δ 1.64 (s, 3H, 1), δ 7.01 (s 1H, 2), δ 7.41 - 7.49 (m, 12H, 3), δ 8.00 (t, 
2H, 4), δ 8.71 (s, 1H, 5), δ 11.99 (s, 1H, 6) 
vii. (S)-2-benzamido-N-(1-phenylethyl)benzamide 22: 
Experimental procedure for 19 was repeated here.  
1-phenylpiperazine (75.1 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl 
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol, 
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40 μL, 1.4 mol equiv) in acetonitrile (5 mL)  yielded 48 mg (0.140 mmol, 36%) of 22 as 
a white precipitate. 
1H NMR (CDCl3): δ 1.64 (s, 1H, 1), δ 6.89 (s, 1H, 2), δ 6.97 (t, 1H, 3), δ 7.36 - 7.49 (m, 
11H, 4), δ 7.99 (d, 2H, 5), δ 8.69 (s, 1H, 6), δ 11.97 (s, 1H, 7) 
viii. N-(2-(4-phenylpiperazine-1-carbonyl)phenyl)benzamide 23: 
Experimental procedure for 19 was repeated here.  
2-aminobenzothiazole (70 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl 
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol, 
40 μL, 1.4 mol equiv) in acetonitrile (5 mL)  yielded 75 mg (0.195 mmol, 51%) of 23 as 
a white powder. 
1H NMR (DMSO): δ 3.19 (s, 4H, 1), δ 3.74 - 3.92 (dd, 4H, 2), δ 6.93 (m, 3H, 3), δ 7.16 
(m, 1H, 4), δ 7.27 (m, 3H, 5), δ 7.49 (m, 4H, 6), δ 7.94 (t, 2H, 7), δ 8.49 (d, 1H, 8), δ
10.11 (s, 1H, 9) 
ix. 2-benzamido-N-(benzo[d]thiazol-2-yl)benzamide 24: 
Experimental procedure for 19 was repeated here.  
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2-aminobenzothiazole (70 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl 
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol, 
40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 30 mg (0.081 mmol, 21%) of 24 as a 
white solid precipitate. 
1H NMR (DMSO): δ 7.32 (m, 3H, 1), δ 7.45 (t, 1H, 2), δ 7.56 - 7.72 (m, 7H, 3), δ 7.95 
(d, 2H, 4), δ 12.17 (s, 1H, 5)  
LC/MS: Calc. For C21H15N3O2S : 373.09; found 374 
x. N-(2,3-dihydro-1H-inden-2-yl)-2-nitrobenzamide 25: 
To a solution of 2-aminoindan (200 mg, 1.18 mmol, 1.0 mol equiv) in pyridine (5 mL) 
was added 2-nitrobenzenesulfonyl chloride (315 mg, 1.42 mmol, 1.2 mol equiv). The 
reaction was stirred at room temperature for approximately four hours. The reaction was 
then poured into 1 N HCl (20 mL) where the organic layer was extracted using ethyl 
acetate (45 mL). Following this, the organic layer was washed with brine (20 mL), dried 
over sodium sulfate, filtered, and concentrated. The product was recrystallized in DCM/
hexane to give pure yellow crystals with 54% yield (180.7 mg, 0.641 mmol).  
1H NMR (Acetone-d6): δ 3.08 (dd, H, 1), δ 3.37 (dd, H, 2), δ 4.85 (m, H, 3), δ 7.20 - 
7.27 (dd, H, 4), δ 7.68 - 7.81 (m, H, 5), δ 8.05 (d, H, 6) 
xi. 2-amino-N-(2,3-dihydro-1H-inden-2-yl)benzamide 26:  
To a Parrbottle, Pd/C (20 mg, 20% by weight) was added followed by the slow addition 
of methanol (10 mL) and 25 (100 mg, 0.355 mmol). The bottle was placed in the 
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ParrShaker at 28 psi overnight. The following day, the contents of the flask were poured 
into a filter funnel containing celite and washed with methanol. To assure desired product 
was produced, ninhydrin test was utilized resulting in a ninhydrin positive TLC plate. The 
final product was filtered and concentrated to give a tan solid in 47% yield (45 mg, 0.168 
mmol).
1H NMR (Acetone-d6): δ 3.01 (dd, 2H, 1), δ 3.28 (dd, 2H, 2), δ 4.82 (m, 1H, 3), δ 6.26 
(s, 2H, 4), δ 6.46 (t, 1H, 5), δ 6.72 (d, 1H, 6), δ 7.14 - 7.20 (m, 5H, 7), δ 7.48 (d, 1H, 8), δ
7.75 (s, 1H, 9) 
xii. 2-benzamido-N-(2,3-dihydro-1H-inden-2-yl)benzamide 27: 
The benzoyl chloride (52 mg, 0.373 mmol, 2 mol equiv) was added to a solution of 26
(50 mg, 0186 mmol, 1 mol equiv) with triethylamine (47 mg, 0.465 mmol, 2.5 mol equiv) 
in DMF (3 mL). The reaction proceeded to be stirred at room temperature for two hours. 
Subsequently, the reaction was poured into water (10 mL) and the organic layer was 
extracted using ethyl acetate (30 mL). The organic layer was then washed with 1 N HCl 
(20 mL), sodium bicarbonate (20 mL), and brine (20 mL). Organic layer was then dried 
over sodium sulfate, filtered, and concentrated. The crude product was purified through 
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flash column chromatography (2:1 Hexane/EtOAc) to yield 29 mg of yellow crystals 
(0.081 mmol, 44%). 
1H NMR (Acetone-d6): δ 3.01 (dd, 2H, 1), δ 3.44 (dd, 2H, 2), δ 4.96 (m, 1H, 3), δ 7.06 - 
7.16 (m, 5H, 4), δ 7.59 (m, 4H, 5), δ 7.86 (d, 1H, 6), δ 8.06 (t, 2H, 7), δ 8.42 (a, 1H, 8), δ
8.87 (d, 1H, 9) 
LC/MS: Calc. For C23H20N2O2 : 356.15; found 357.5 
xiii. N-(1-methyl-1H-benzoimidazol-2-yl)-2-nitrobenzenesulfonamide 28: 
In a round bottom flask, 2-amino-1-methylbenzimidazole (100 mg, 0.680 mmol, 1.0 mol 
equiv) was dissolved in chloroform (10 mL) and treated successively 2-
nitrobenzenesulfonyl chloride (300 mg, 1.360 mmol, 2.0 mol equiv). To the solution, 
triethylamine (171 mg, 1.700 mmol, 125 μL, 2.5 mol equiv) and DMAP (25 mg, 0.200 
mmol, 0.3 mol equiv) were added. The mixture was refluxed overnight under nitrogen in 
an oil bath heated to 65°C. The following day, the reaction was poured into DCM (10mL) 
where the organic layer was washed with 1 N HCL (30 mL) and brine (10 mL), dried 
over sodium sulfate, filtered, and concentrated. The crude product was purified using 
flash column chromatography (2:1 Hexane/EtOAc) to give a yellow solid precipitate. The 
desired product was acquired in 34% yield (76.6 mg, 0.231 mmol). 
1H NMR (Acetone-d6): δ 3.56 (s, 3H, 1), δ 7.29 (m, 2H, 2), δ 7.43 (d, 1H, 3), δ 7.54 (d, 
1H, 4), δ 7.78 (t, 2H, 5), δ 8.16 (m, 1H, 6), δ 8.32 (d, 1H, 7) 
xiv. 2-amino-N-(1-methyl-1H-benzo[d]imidazol-2-yl)benzenesulfonamide 29:  
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In a Parbottle, Pd/C (40 mg, 20% by weight) was added followed by the addition of 
acetic acid (10 mL) and 28 (200 mg, 0.602 mmol). The bottle was placed in the 
ParrShaker at 40 psi overnight. The contents of the flask were poured into a filter funnel 
containing celite and washed with excess acetic acid, then concentrated down. Toluene 
was added to form an azeotrope with acetic acid before being evaporated off which was 
repeated three times with 10 mL of toluene. To insure the desired product was produced, 
ninhydrin test was used resulting in a ninhydrin positive TLC plate. Reaction yielded 100 
mg of tan solid product (0.276 mmol, 55%). 
1H NMR (Acetone-d6): δ 3.32 (s, 3H, 1), δ 6.58 (t, 1H, 2), δ 6.68 (t, 1H, 3), δ 6.81 (d, 
1H, 4), δ 6.87 (d, 1H, 5), δ 7.44 (d, 1H, 6), δ 7.76 (dd, 2H, 7), δ 7.84 (d, 1H, 8) 
xv. N-(2-(N-(1-methyl-1H-benzo[d]imidazol-2-yl)sulfamoyl)phenyl)benzamide 30: 
In a reaction vial, 2-(N-(1-methyl-1H-benzo[d]imidazol-2-yl)sulfamoyl)benzenaminium  
 (200 mg, 0.552 mmol, 1.0 mol equiv) was dissolved in acetonitrile ( 5 mL) and treated 
successively with triethylamine (167 mg, 1.657 mmol, 120 μL, 3 mol equiv), DMAP (40 
mg, 20% by weight), and benzoyl chloride (232 mg, 1.657 mmol, 280 μL, 3.0 mol 
equiv). The vial was sealed and placed in a 65°C to stir overnight. Following this, the 
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reaction was poured into ethyl acetate (10mL) where the organic layer was washed with 
water (15 mL), sodium bicarbonate (10 mL),  and brine (10 mL). Organic layer was dried 
over sodium sulfate, filtered, and concentrated. The crude product was purified using 
flash column chromatography (1:1 Hexane/EtOAc) to give a tan solid precipitate. The 
desired product was acquired in 31% yield (70 mg, 0.172 mmol).
1H NMR (Acetone-d6): δ 3.35 (s, 3H, 1), δ 7.21 (m, 3H, 2), δ 7.31 (d, 1H, 3), δ 7.45 (dd, 
1H, 4), δ 7.60 (m, 4H, 5), δ 8.03 (d, 1H, 6), δ 8.17 (dd, 2H, 7), δ 8.65 (d, 1H, 8), δ 10.48 
(s, 1H, 9), δ 11.19 (s, 1H, 10) 
LC/MS: Calc. For C21H18N4O3S : 406.11; found 407 
xvi. N-(2,3-dihydro-1H-inden-2-yl)-2-nitrobenzenesulfonamide 31: 
Experimental procedure for 25 was repeated here except in an oil bath heated to 55°C. 
2-aminoindan (200 mg, 1.18 mmol, 1.0 mol equiv) and 2-nitrobenzenesulfonyl chloride 
(315 mg, 1.42 mmol, 1.2 mol equiv) in pyridine (5 mL) yielded 288.6 mg of pure yellow 
crystals (0.908 mmol, 77%). 
1H NMR (Acetone-d6): δ 2.99 (dd, 2H, 1), δ 3.19 (dd, 2H, 2), δ 4.45 (m, 1H, 3), δ 7.18 
(m, 4H, 4), δ 7.99 (m, 3H, 5), δ 8.27 (d, 1H, 6) 
xvii. 2-amino-N-(2,3-dihydro-1H-inden-2-yl)benzenesulfonamide 32: 
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In a 3-neck round bottom flask, the weighed out Pd/C (20 mg, 20% by weight) was added 
followed by the slow addition of methanol (14 mL) and 31 (100 mg, 0.315 mmol) under 
nitrogen. A balloon apparatus was attached in place of nitrogen, then the system was 
flushed three times under vacuum. Allowed the solution to stir for approximately two 
hours. To assure desired product was produced, ninhydrin test was utilized resulting in a 
ninhydrin positive TLC plate. Then, the contents of the flask were poured into a filter 
funnel containing celite and washed with methanol. The final product was filtered and 
concentrated to give a tan solid in 65% yield (62 mg, 0.204 mmol). 
1H NMR (Acetone-d6): δ 2.85 (dd, 2H, 1), δ 2.99 (dd, 2H, 2), δ 4.02 (m, 1H, 3), δ 5.68 
(s, 2H, 4), δ 6.72 (t, 1H, 5), δ 6.90 (s, 1H, 6), δ 6.92 (d, 1H, 7), δ 7.10 (m, 4H, 8), δ 7.32 
(t, 1H, 9), δ 7.68 (d, 1H, 10) 
xviii. N-(2-(N-(2,3-dihydro-1H-inden-2-yl)sulfamoyl)phenyl)benzamide 33: 
A solution of 32 (50 mg, 0.164 mmol, 1 mol equiv) and benzoyl chloride (28 mg, 0.197 
mmol, 1.2 mol equiv) in pyridine (2 mL) were stirred in an oil bath heated to 65°C 
overnight. The following day, the reaction was poured into 1 N HCl (20 mL) where the 
organic layer was extracted using ethyl acetate (30 mL). Following this, the organic layer 
was washed with excess 1 N HCl (20 mL), sodium bicarbonate (20 mL), and brine (20 
mL). Organic layer was then dried over sodium sulfate, filtered, and concentrated. The 
44
crude product was purified through flash column chromatography (2:1 Hexane/EtOAc) to 
yield 17 mg of white powder (0.043 mmol, 25%). 
1H NMR (Acetone-d6): δ 2.78 (dd, 2H, 1), δ 3.01 (dd, 2H, 2), δ 4.26 (m, 1H, 3), δ 7.07 
(m, 4H, 4), δ 7.33 (t, 1H, 5), δ 7.54 (m, 2H, 6), δ 7.62 (d, 1H, 7), δ 7.74 (t, 1H, 8), δ 7.99 
(d, 1H, 9), δ 8.12 (d, 1H, 10), δ 8.73 (d, 1H, 11) 
LC/MS: Calc. For C22H20N2O3S : 392.12; found 393 
xix. N-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-nitrobenzamide 39: 
2-amino-1-methylbenzimidazole (265 mg, 1.802 mmol, 1.0 mol equiv) was dissolved in 
pyridine (6 mL) followed by the addition of 2-nitrobenzoyl chloride (400 mg, 2.162 
mmol, 1.2 mol equiv). The contents of the flask were stirred at 60°C for around four 
hours. The pyridine was then evaporated off and the remaining contents were dissolved 
into ethyl acetate (20 mL) where the organic layer was extracted using ethyl acetate (45 
mL). The organic layer was washed with sodium bicarbonate (20 mL) and brine (20 mL). 
The solid material was filtered out and organic layer was dried over sodium sulfate, 
filtered, and concentrated. Purification of the crude product was completed on a flash 
column chromatography (2:1 Hexane/EtOAc) to give a pure white solid precipitate with 
30% yield (160 mg, 0.541 mmol).  
1H NMR (DMSO): δ 3.47 (s, 3H, 1), δ 7.87 (d, 1H, 2), δ 7.46 - 7.59 (m, 3H, 3), δ 7.67 
(m, 1H, 4), δ 7.82 (m, 1H, 5), δ 8.11 (d, 1H, 6), δ 8.39 (d, 1H, 7) 
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LC/MS: Calc. For C15H12N4O3 : 296.09; found 297.6 
xx. 2-amino-N-(1-methyl-1H-benzo[d]imidazol-2-yl)benzamide 40: 
39 (200 mg, 0.676 mmol) was dissolved in a 9:1 ethyl acetate/methanol solution (50 mL) 
in a 125 Erlenmeyer flask using a heat gun. Pd/C (40 mg, 20% by weight) was added to a 
Parbottle followed by the addition of the above solution. The bottle was then placed in 
the ParrShaker at 40 psi overnight. The next day, the contents of the flask were poured 
into a filter funnel containing celite and washed with excess methanol. To assure the 
correct product was produced, ninhydrin test was used resulting in a ninhydrin positive 
TLC plate. The final product was concentrated to give a white solid in 95% yield (190 
mg, 0.714 mmol). 
1H NMR (Acetone-d6): δ 3.82 (s, 3H, 1), δ 6.53 (t, 1H, 2), δ 7.31 (t, 1H, 3), δ 7.37 (m, 
1H, 4), δ 7.52 (d, 1H, 5), δ 7.65 (d, 1H, 6), δ 7.78 (t, 1H, 7), δ 8.39 (dd, 1H, 8), δ 8.56 (d, 
1H, 9)
xxi. N-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-(phenylsulfonamido)benzamide 41: 
Experimental procedure for 30 was repeated here.  
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40 (50 mg, 0.1879, 1 mol equiv) treated with triethylamine (57 mg, 0.5639 mmol, 41 μL, 
3 mol equiv), DMAP (13 mg, 25% by weight), and sulfonyl chloride (100 mg, 0.5639 
mmol, 137 μL, 3.0 mol equiv) in acetonitrile (4 mL) produced 35 mg of a white solid 
precipitate (0.086 mmol, 46%). 
1H NMR (Methanol): δ (s, 3H, 1), δ 7.33 - 7.43 (m, 4H, 2), δ 7.48 - 7.56 (m, 3H, 3), δ
7.78 (d, 1H, 4), δ 7.61 (d, 1H, 5), δ 7.79 (q, 2H, 6), δ 8.32 (d, 1H, 7), δ 8.57 (d, 1H, 8) 
LC/MS: Calc. For C21H18N4O3S : 406.11; found 407
xxii. N-(2,3-dihydro-1H-inden-2-yl)-2-(phenylsulfonamido)benzamide 42: 
Experimental procedure for 27 was repeated here except with sulfonyl chloride. 
Compound 26 (50 mg, 0.186 mmol, 1.0 mol equiv) mixed with triethylamine (47 mg, 
0.465 mmol, 2.5 mol equiv) and benzoyl chloride (66 mg, 0.373 mmol, 2 mol equiv) in 
DMF (3 mL) yielded 9 mg of pure white crystals (0.023 mmol, 12%).  
1H NMR (Acetone-d6): δ 3.38 (dd, 2H, 1), δ 3.55 (dd, 2H, 2), δ 4.73 (m, 1H, 3), δ 7.02 
(t, 1H, 4), δ 7.16 (, 4H, 5), δ 7.48 (t, 1H, 6), δ 7.52 (m, 4H, 7), δ 7.69 (d, 1H, 8), δ 7.76 
(m, 1H, 9), δ 8.31 (d, 1H, 10) 
LC/MS: Calc. For C22H20N2O3S : 392.12; found 393.6
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